Abstract
BackgroundImvax is developing a novel personalized immunotherapeutic platform combining irradiated patient-derived tumor cells and insulin-like growth factor type-1 receptor antisense oligonucleotide (IMV-001) in biodiffusion chambers (BDC; 0.1-micron pores). The combination...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have